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Sir,
A recent paper by Lundgren-Nilsson & Tennant (1) and ac-
companying commentary (2) reviewed the development of 
Rasch analysis in rehabilitation. The authors of the two papers 
acknowledge the advances that have been made in terms of 
analysis. However, they did not highlight an important issue 
with regards to the use of Rasch measures once developed. We 
believe this is a fundamental issue that needs to be addressed 
to ensure the potential of Rasch is fulfilled.
There has been a recognised increase in Rasch analysis in 
rehabilitation (3, 4), with Lundgren-Nilsson & Tennant (1) 
reporting over 50 papers applying Rasch to the Functional 
Independence Measure. Given the importance of measurement 
in clinical trials and clinical practice, it would seem logical 
that a technique that enabled ‘better’ measures and improved 
interpretation (5) would have been welcomed by both the 
research and clinical communities. Rasch analysis has the 
advantage of interval level measurement which has potential 
to allow parametric analysis in clinical trials, improve syn-
thesis in systematic reviews and map individual and service 
outcomes over time in a more robust manner. However, the 
extent to which Rasch developed and refined measures have 
been used in research or practice has not been investigated. 
It has been supposed that Rasch analysis is rarely applied to 
practical implementation of outcome measures (3). We under-
took a review to explore how often Rasch developed scales 
have been used in research. 
RevIeW oN uSe oF RASCH deveLoped MeASuReS
The review methodology as detailed by Tesio et al. (3) was 
repeated, searching for Rasch as free text. published articles 
that specified they applied Rasch developed or refined meas-
ures to a study were included. The entire electronic databases 
Medline, eMBASe, Cinahl, pedro, Cochrane Central Register 
of Controlled Trials, and Cochrane database of Systematic 
Reviews, psychINFo and Web of Science searched from the 
earliest publication to June 2011. 
Initially the number of studies using Rasch analysis were 
documented to compare with Tesio et al. (3) to document 
the increase in Rasch analysis over the last 4 years. The title 
and/or abstract of articles identified from the initial Medline 
search were then examined to identify those papers which had 
applied a Rasch developed or derived scale to clinical trials, 
case studies or clinical practice. 
From the initial search of the electronic databases, it was 
clear that the use of Rasch analysis has continued to increase 
across all of the databases (Table I). 
From the initial Medline search which retrieved 1,458 arti-
cles, only 25 studies were found that applied Rasch developed 
or refined measures to clinical trials, case studies or clinical 
practice. Four of these were randomized controlled trials, with 
the remainder split between correlation or regression studies, 
case studies, cohort studies or retrospective analysis. The earliest 
study found applying Rasch measures was in 2002 (6). The main 
field which has implemented the application of Rasch analysis 
in studies is in vision and rehabilitation, with 10 out of the 25 
studies on this area (4 by Lamoureux and colleagues (7–10). 
Most of the excluded studies had used Rasch in the development 
or refining of measures but not the application and there were a 
number of reviews and methodological reports.
It is recognized that there are obvious limitations in the 
search procedure and it may not be comprehensive. The review 
method may have some elements of bias and have underes-
timated the number of studies which applied Rasch. There 
may be an unknown number of papers where Rasch-derived 
scales are used, but the word Rasch is not mentioned in a way 
identified by the search. However, 25 studies equates to ap-
proximately 1.8% of the number of studies published on Rasch 
analysis actually applying it so it is hypothesized that the use of 
Rasch scales in clinical outcome research does not correspond 
to the use of Rasch in outcome measure development. 
These results are consistent with those found be Tesio et 
al. (3) and Belvedere & de Morton (4). Bond (11) recognized 
this discrepancy, questioning why Rasch measurement is well-
used in the development and refinement of measures but not in 
measuring patients. There is a gap between psychometricians 
and applied researchers, with researchers themselves slow to 
apply Rasch-derived measures. even researchers who are co-
authors on Rasch measure development/interpretation papers 
have then done further studies and not used the Rasch versions 
but the original non-Rasch scales. 
CoMMeNTARy oN “pAST ANd pReSeNT ISSueS IN RASCH ANALySIS:  
THe FIM RevISITed”
Table I. Results of the initial search compared with Tesio et al., 
2007(3)
Articles retrieved 
until May 2007 (3)
n
Articles retrieved 
until June 2011
n
Medline 799 1,458
embase 821 1,881
Cinahl 344 1,267
pedro 1 6
Cochrane 13 24
psycINFo 1,228 1,928
Web of Science 1,025 2,447 when searched 
in all databases as 
‘topic’
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There has been no research specifically investigating factors 
affecting uptake, but several reasons have been postulated. A 
letter by Granger (12) stated 10 obstacles to Rasch analysis. A 
major recognized barrier is the need for specialist knowledge in 
terms of mathematical understanding, and the need for special-
ist software (5). Few researchers or clinicians are trained in its 
use and interpretation. This makes it essential that Rasch scales 
are accessible in a format that eases interpretation. It should be 
encouraged that researchers publish conversion tables, ideally 
through a website. Franchignoni et al. (13) recognizes that often 
papers do not include conversion tables showing the relation-
ship between ordinal raw scores and the corresponding Rasch 
interval measures and mentions that Abilhand website with an 
online Rasch analysis routine enables the conversion.
The challenge to Rasch researchers to demonstrate the use-
fulness of Rasch and facilitate application of Rasch measures 
in research and practice was given by Tesio (14) in 2008, yet in 
2011 little has changed. The danger of Rasch being restricted 
to being used by a small community of outcome measure 
researchers (3) remains a reality. The measure development 
process should not end once psychometric properties been 
demonstrated, there is a need to look at implementation is-
sues too. As identified by Krumholz (15), outcome measure 
researchers must build partnerships with those who will use 
the measures developed. The suggestion by Heinemann & 
deutsch (2) that journal editors request the use of contemporary 
psychometric measures or explicitly state this limitation may 
be one way forward.
The use of Rasch analysis in rehabilitation continues to grow 
but it is hypothesized that this increase is not being matched 
by an increase in the application of Rasch-derived measures in 
applied research. We agree that Rasch has the potential to add 
much to rehabilitation and the process continues to develop. 
However, when discussing future issues we feel that it is amiss 
not to discuss issues with the use of Rasch measures in applied 
research. It has to be questioned what the use of the increase 
in Rasch analysis in rehabilitation research is, if then these 
measures are published in a non-useable format and are never 
used in research. There is an urgent need for investigation of 
the reasons for non-uptake. There is a plea for researchers to 
minimize the barriers already identified to uptake by ensuring 
Rasch scales are published in an accessible format and publish 
conversion tables, ideally through a website. It is also important 
to define when such tables could be used and the premises 
for their use. outcome researchers need to change behaviour 
themselves, using Rasch-derived scales when possible and 
appropriate, to increase the visibility and advantages of using 
interval levels scales for investigating change scores over time 
so they are more familiar to other researchers and clinicians. 
There is a need for closer working between researchers and 
end users of measures, with measure development continuing 
beyond publication of sufficient psychometric properties, but 
continuing into uptake and application. 
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While we welcome the continuing emphasis given by Connell 
& Sutton to the need for Rasch-based scales for rehabilitation 
outcomes, we would argue that the premise of their work, and 
that of Tesio and colleagues (1) beforehand, has limitations. Try-
ing to find out if Rasch-based measures are used, they perform a 
systematic search in MedLINe using the text word ‘Rasch’. 
Why, we ask, should any Rasch developed scale which is 
subsequently used in a study, mention Rasch? With scales 
developed by classical approaches, would we expect to find 
them in use if, for example, we searched for ‘Confirmatory 
Factor Analysis’ (CFA)? once the scale is developed, it can be 
widely used with just the reference to the original development 
paper, and no mention of the methodology used. This may not 
even appear in the title of the development paper, and so no 
amount of searching for ‘Rasch’ (or CFA) would uncover that 
such a scale, developed with a particular methodology, had 
been used. An example of this would be a paper on work pro-
ductivity in ankylosing spondylitis (AS) (2). That paper used 
the AS Quality of life Questionnaire (ASQoL), a needs-based 
disease specific quality of life scale for AS developed with the 
benefit of Rasch analysis (3). The text word ‘Rasch’ does not 
appear at all in the paper by Maksymowych et al. (2). To do 
the search properly for those scales used in outcome studies, 
it would require that all scales developed (or modified) with 
the benefit of Rasch analysis should be first identified, and 
then each individually subjected to a MedLINe search. For 
example, the ASQoL development paper mentioned above 
has currently 150 citations (Google Scholar), which gives an 
indication of how much it may have been used. 
Where ‘Rasch’ should be mentioned in a paper using an exist-
ing scale is where the interval scale transformation is used for 
analysis. For many, this is the prime purpose of applying the 
Rasch model in health outcomes. Indeed it is this application 
that should be encouraged as the misuse of ordinal scales is 
still endemic in the literature, despite numerous exhortations 
to the contrary (e.g. 4). Thus the production of transformation 
tables which allow those in both clinical and outcome settings to 
make use of the transformation, where needed, should become a 
routine part of all development papers, given the sample size is 
sufficient for that purpose. In this way we can all benefit from the 
special properties conferred by the Rasch measurement model, 
whether the scale is used in a routine clinical setting to identify 
risk, or to monitor progress; whether it is used in an outcome 
study, or in a randomised controlled trial. When this transforma-
tion is used for the analysis of outcomes of any kind, then we 
would expect the word ‘Rasch’ to appear in any search.
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